Comparison · NCT05579249-sae
Semaglutide 2.4 mg vs Other Anti-obesity Medications (AOMs): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Semaglutide 2.4 mg vs Other Anti-obesity Medications (AOMs): serious adverse events. Trial comparisons, record NCT05579249-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05579249-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0124 | 0.00422 | 0.0358 | wilson | |
| Risk in group 2 | 0.0331 | 0.0168 | 0.0639 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0207 | -0.0525 | 0.00782 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.375 | 0.101 | 1.4 | log | |
| Odds ratio, group 1 over group 2 | 0.367 | 0.0962 | 1.4 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Semaglutide 2.4 mg than on Other Anti-obesity Medications (AOMs) | 48.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Semaglutide 2.4 mg | Participants received once weekly semaglutide 2.4 milligrams (mg) subcutaneous (s.c) injection for 52 weeks as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management. | 3 | 242 | EG000 |
| Group 2 | Other Anti-obesity Medications (AOMs) | Participants received one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management. The 4 anti-obesity medications were orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection. | 8 | 242 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From week 0 to week 52
Source ClinicalTrials.gov
Trial
- Title
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
- NCT number
- NCT05579249
- Phases
- PHASE4
- Conditions
- Obesity
- Interventions
- Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
- Lead sponsor
- Novo Nordisk A/S
- Results first posted
- 2026-01-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05579249?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05579249-sae